MARS Holter Analysis Workstation is designed for acquisition, analysis, edit, review, report and storage of ambulatory ECG and multi-parameter data. Results of the automated analysis are intended to assist the physician in the interpretation of the recorded data. This information is not intended to serve as a substitute for the physician overread of the recorded ECG data. The MARS Holter Analysis Workstation is intended to be used by trained operators under the direct supervision of a licensed healthcare practitioner in a hospital or clinic environment. Patient population includes both adult and pediatric (greater than 10Kg) human patients. The MARS Holter Analysis Workstation provides the user arrhythmia studies and Holter analysis capabilities. Data acquired may be used for the following indications:

Evaluation of symptoms that may be caused by cardiac arrhythmia and/or conduction disturbances
Evaluation of symptoms that may be due to myocardial ischemia
Detection of ECG events that alter prognosis in certain forms of heart disease
Detection and analysis of pacemaker function and failure
Determination of cardiac response to lifestyle
Evaluation of therapeutic interventions
Investigations in epidemiology and clinical trials

Device Description

The MARS Holter Analysis Workstation system is a software-system that runs on PC based hardware. The MARS Holter Analysis Workstation supports a number of software applications including analysis, user editing and final report processing.
The MARS Hotter Analysis Workstation analyzes ECG data, to detect and label beats, and then presents it in a variety of screens to the user for review and data editing purposes. The MARS Holter Analysis Workstation system stores and prints final reports and allows reports to be sent to the MUSE Cardiology Information Management System for long- term archive.
The MARS Holter Analysis Workstation supports acquisition from ambulatory ECG Recorders and multi-parameter data from the CIC Pro Clinical Information Center. A variety of different final report formats can be stored and printed. The final report is used by trained medical personal to diagnose a patient's cardiac abnormalities.

AI/ML Overview

This submission concerns the GE MARS Holter Analysis Workstation, an ECG analysis software system. The device did not require clinical studies, as it was determined to be substantially equivalent to a predicate device (MARS Holter Analysis Workstation K#093141). Therefore, there is no information about specific acceptance criteria or related studies as you would typically find for a new device requiring clinical validation.

Here's the breakdown of the information requested, based on the provided text:

1. A table of acceptance criteria and the reported device performance

No specific performance acceptance criteria or reported device performance values were listed in the provided document. The submission states that the device is "as safe, as effective, and performance is substantially equivalent to the predicate device."

2. Sample size used for the test set and the data provenance

Not applicable, as no clinical studies with a test set were conducted.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

Not applicable, as no clinical studies with a test set were conducted.

4. Adjudication method for the test set

Not applicable, as no clinical studies with a test set were conducted.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. The device is a software system intended to assist physicians in interpretation, not to replace it, and no MRMC study was mentioned. The submission explicitly states: "Results of the automated analysis are intended to assist the physician in the interpretation of the recorded data. This information is not intended to serve as a substitute for the physician overread of the recorded ECG data."

6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done

The document does not explicitly describe a standalone algorithm performance study. However, the mention of "Performance testing (Verification)" and adherence to standards like AAMI EC-57:1998 (R2008) "Testing and reporting performance results of cardiac rhythm and ST segment measurement algorithms" suggests that the algorithm's performance was evaluated internally, likely in a standalone manner against established benchmarks or annotated datasets. Specific results are not provided in this summary.

7. The type of ground truth used

For any internal performance testing (referring to adherence to AAMI EC-57), the ground truth would typically be established by expert consensus or meticulously annotated datasets designed for such algorithmic testing. However, the document does not specify the exact type of ground truth used for such internal verifications.

8. The sample size for the training set

Not applicable. The document does not provide details about a training set, as it emphasizes substantial equivalence to a predicate device and does not describe the development or validation of a new AI model in detail.

9. How the ground truth for the training set was established

Not applicable, as no training set details are provided.

Summary

{0}------------------------------------------------

DEC 0 4 2013

Image /page/0/Picture/1 description: The image shows the General Electric (GE) logo. The logo consists of the letters "G" and "E" intertwined within a circle. The logo is black and white and has a vintage look.

GE Healthcare 510(k) Premarket Notification Submission

510(k) Summary

In accordance with 21 CFR 807.92 the following summary of information is provided:

August 1. 2013 Date:

GE Medical Systems Information Technologies Submitter: 9900 Innovation Drive Wauwatosa, WI 53226

Primary Contact Person:

Kristin Pabst Regulatory Affairs Manager GE Medical Systems Information Technologies Phone: (414) 721-3104 Fax: (414) 721-3863

Secondary Contact Person:

Device:

Doug Kentz Regulatory Affairs GE Medical Systems Information Technologies Phone (414) 362-2038 FAX: (414) 362-2585

Trade Name: MARS Holter Analysis Workstation

Common/Usual Name: ECG Analysis Computer

Classification Names: Programmable Diagnostic Computer (21 CFR 870.1425)

Product Code: DOK

Predicate Device(s): MARS Holter Analysis Workstation K#093141

Device Description:

The MARS Hotter Analysis Workstation analyzes ECG data, to detect and label beats, and then presents it in a variety of screens to the user for review and data editing purposes. The MARS Holter Analysis Workstation system stores and prints final reports and allows reports to be sent to the MUSE Cardiology Information Management System for long- term archive.

The MARS Holter Analysis Workstation supports acquisition from ambulatory ECG Recorders and multi-parameter data from the CIC Pro Clinical Information Center. A variety of different final report formats can be stored and printed. The final report is used by trained medical personal to diagnose a patient's cardiac abnormalities.

MARS Holter Analysis Workstation is designed for acquisition, analysis. Intended Use: edit, review, report and storage of ambulatory ECG and multiparameter data. Results of the automated analysis are intended to assist the physician in the interpretation of the recorded data. This information is not intended to serve as a substitute for the physician overread of the recorded ECG data. The MARS Holter Analysis Workstation is intended to be used by trained operators under the direct supervision of a licensed healthcare practitioner in a hospital or clinic

{1}------------------------------------------------

Image /page/1/Picture/1 description: The image shows the General Electric (GE) logo. The logo consists of the letters "GE" intertwined and enclosed within a circle. The logo is black and white and has a vintage look.

Determination of Substantial

Equivalence:

GE Healthcare

510(k) Premarket Notification Submission

environment. Patient population includes both adult and pediatric (greater than 10Kg) human patients. The MARS Holter Analysis Workstation provides the user arrhythmia studies and holter analysis capabilities.

Data acquired may be used for the following indications:

. Evaluation of symptoms that may be caused by cardiac arrhythmia and/or conduction disturbances
. Evaluation of symptoms that may be due to myocardial ischemia
Detection of ECG events that alter prognosis in certain forms of . heart disease
. Detection and analysis of pacemaker function and failure
Determination of cardiac response to lifestyle .
Evaluation of therapeutic interventions .
Investigations in epidemiology and clinical trials

The proposed MARS Holter Analysis Workstation is a software device Technology: that runs on IT hardware employing the same functional scientific technology as the predicate device MARS Holter Analysis Workstation (K093141).

Summary of Non-Clinical Tests:

The MARS Holter Analysis Workstation complies with voluntary standards:

IEC 60601-1-1:2000 2nd edition Medical Electrical . Equipment - Part 1-1: General Requirements for Safety - Collateral Standard: Safety Requirements for Medical Electrical Systems
IEC 60601-1-2:2007 Medical Electrical Equipment -◆ Part 1-2: General Requirements for Safety - Collateral standard: Electromagnetic Compatibility Requirements and Tests, Edition 3
. IEC 60601-1-4:1996, +A1:1999 (AKA IEC 60601-1-4:2000) Medical Electrical Equipment - Part 1-4: General Requirements for Safety - Collateral Standard: Programmable Electrical Medical Systems
AAMI EC-57: 1998 (R2008) Testing and reporting . performance results of cardiac rhythm and ST seament measurement algorithms

The following quality assurance measures are applied to the development of the system:

Requirements Definition .
Risk Analysis .
. Requirements Reviews
Design Reviews .
Code Inspection .
Testing on unit level (Module verification) .
Integration testing (Module and System verification) .

Page 2 of 3

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the General Electric (GE) logo. The logo consists of the letters 'G' and 'E' intertwined within a circular border. The letters are stylized and appear to be in a cursive font.

GE Healthcare

510(k) Premarket Notification Submission

Performance testing (Verification) .
Final Acceptance testing (Validation) .
Safety testing (Verification) .

Summary of Clinical Tests:

The subject of this premarket submission, MARS Holter Analysis Workstation, did not require clinical studies to support substantial equivalence.

Conclusion:

GE Healthcare considers the MARS Holter Analysis Workstation to be as safe, as effective, and performance is substantially equivalent to the predicate device.

{3}------------------------------------------------

Public Health Service

Image /page/3/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES U.S.A." arranged around the perimeter. Inside the circle is a stylized symbol featuring a human figure embracing a three-barred cross, which is the symbol of the Public Health Service.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring. MI) 20993-0002

December 4, 2013

GE Medical Systems Information Technologies, Inc. Kristin Pabst 9900 West Innovation Drive Wauwatosa. WI 53226 US

Re: K132437

Trade/Device Name: MARS HOLTER analysis workstation Regulation Number: 21 CFR 870.14257 Regulation Name: Programmable Diagnostic Computer Regulatory Class: Class II Product Code: DQK Dated: November 5, 2013 Received: November 5, 2013

Dear Kristin Pabst:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices. good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA). it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act

{4}------------------------------------------------

Page 2 - Kristin Pabst

or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours.

OwenFDEaris -S

for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

Image /page/5/Picture/1 description: The image shows a black and white logo of General Electric (GE). The logo consists of the letters "GE" intertwined within a circle. The letters are stylized with curved lines, giving them a classic, almost handwritten appearance.

GE Healthcare 510(k) Premarket Notification Submission

510(k) Number: K132437

Device Name: MARS Holter Analysis Workstation

Indications for Use:

MARS Holter Analysis Workstation is designed for acquisition, analysis, edit, review, report and storage of ambulatory ECG and multi-parameter data. Results of the automated analysis are intended to assist the physician in the interpretation of the recorded data. This information is not intended to serve as a substitute for the physician overread of the recorded ECG data. The MARS Holter Analysis Workstation is intended to be used by trained operators under the direct supervision of a licensed healthcare practitioner in a hospital or clinic environment. Patient population includes both and pediatric (greater than 10Kg) human patients. The MARS Holter Analysis Workstation provides the user arrhythmia studies and Holter analysis capabilities. Data acquired may be used for the following indications:

Evaluation of symptoms that may be caused by cardiac arrhythmia and/or conduction ● disturbances
Evaluation of symptoms that may be due to myocardial ischemia .
Detection of ECG events that alter prognosis in certain forms of heart disease .
Detection and analysis of pacemaker function and failure .
Determination of cardiac response to lifestyle .
Evaluation of therapeutic interventions .
Investigations in epidemiology and clinical trials .

Prescription Use X AND/OR (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (Part 21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Image /page/5/Picture/18 description: The image shows a signature and a digitally signed stamp. The stamp indicates that the document was digitally signed by Owen Faris -S. The date of the signature is 2013.12.04, and the time is 10:22:30-05'00'.

Regulation Number and Section

§ 870.1425 Programmable diagnostic computer.

(a)
Identification. A programmable diagnostic computer is a device that can be programmed to compute various physiologic or blood flow parameters based on the output from one or more electrodes, transducers, or measuring devices; this device includes any associated commercially supplied programs.(b)
Classification. Class II (performance standards).